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Abstract
Background Dimethyl trisulfide (DMTS) is a highly lipid-
soluble cyanide (CN) antidote candidate molecule. In prior
studies with various US FDA-approved co-solvents, sur-
factants, and their combinations, aqueous solutions con-
taining 15% polysorbate 80 (Poly80) were found to
effectively solubilize DMTS in formulations for intra-
muscular administration. However, DMTS formulated in
15% aqueous Poly80 solutions showed gradual losses over
time when stored in vials with septum-based seals.
Objective The present study tested whether storing DMTS
formulations in hermetically sealed glass ampules could
mitigate storage losses.
Methods Samples consisted of 1-mL aliquots of a 50 mg/
ml stock solution of DMTS in 15% aqueous Poly80. The
control samples were stored using a vial-within-a-vial
system—the inner and outer vials were sealed respectively,
with a snap cap, and with a crimped septum. The hermet-
ically sealed test samples were stored in fire-sealed glass
ampules. The DMTS content was measured by HPLC–UV
analysis at specific time points over a 100-day period.
Results While the control samples exhibited systematic
DMTS losses, no DMTS losses were observed from the test
samples stored in hermetically sealed glass ampules over
the 100-day testing period.
Conclusion DMTS formulated in 15% aqueous Poly80
solution has excellent stability when stored in fire-sealed glass
ampules and thus has thepotential to be effectively stored as an
intramuscularCNcountermeasure formass casualty scenarios.
Key Points
An improved storage approach is reported for the
promising cyanide antidote dimethyl trisulfide
(DMTS).
DMTS exhibited no measurable loss over the
100-day study period when stored in hermetically
sealed glass ampules.
1 Introduction
Cyanide (CN) causes toxicity by interfering with cellular
respiration. In humans, the endogenous sulfurtransferase
enzyme rhodanese (Rh) detoxifies CN by converting it to
the less toxic thiocyanate [1, 2]; however, this detoxifica-
tion pathway becomes ineffective when excess CN expo-
sure causes endogenous sulfur donors to be exhausted. For
this reason, antidotes have been developed to counter the
toxicity of CN. Petrikovics et al. [3] recently reviewed CN
detoxification methods, available CN antidotes, and their
properties. In the USA, NithiodoteTM [4] and Cyanokit
[5] are US FDA-approved remedies for CN intoxication.
However, these antidotes require intravenous administra-
tion by trained personnel and therefore are not suitable for
a mass casualty scenario.
One of the key routes of intervention following CN
exposure is the administration of antidotes that serve as
sulfur donors [6, 7]. Thiosulfate is the most important
endogenous sulfur donor [8] and is a key component of the
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currently available antidote NithiodoteTM. Dimethyl
trisulfide (DMTS) is a novel sulfur donor that has shown
superior antidotal potency when compared with thiosulfate
in our previous in vitro and in vivo studies [9]. Acute CN
intoxication can be treated with available antidotes [3] such
as NithiodoteTM (comprising a combination of sodium
thiosulfate and sodium nitrite) [4] and Cyanokit (hy-
droxocobalamin) [5].
DMTS is a naturally occurring oily component of garlic
that exhibits poor water solubility of approximately
0.13 mg/ml [10]. Studies were performed to find formu-
lations with enhanced solubility. The first attempt to for-
mulate this highly lipophilic molecule for intramuscular
administration employed polyethylene glycol-2000 (PEG-
2000)-derived lipid surfactants as micelle-forming agents
[10]. However, the 2.5 mg/ml encapsulation efficiency of
the resulting micellar lipids for DMTS was low. A subse-
quent investigation of additional co-solvents, surfactants,
and combinations identified polysorbate 80 (Poly80), also
known as Tween 80, as a promising solubilizing agent for
DMTS [11]. Poly80 is a surfactant whose critical micelle
concentration (CMC) in water falls in the range of
0.010–0.014 mM [12–14]. Formulation studies showed
that 15% (* 114 mM) Poly80 in water elevated DMTS
solubility more than 600 times (from approx. 0.13 to
86 mg/ml) [11].
Analytical methods were developed for DMTS detection
from formulations, blood, and brain [15, 16]. Methods such
as these enabled us to follow the storage stability of DMTS
in a 15% Poly80 formulation over 29 weeks [17]. By the
end of the 29-week study, samples stored at room tem-
perature exhibited 36–58% reductions in DMTS concen-
tration. The DMTS was stored using a ‘‘matroyshka doll’’
approach in which the DMTS formulation was sealed in a
small glass vial with a snap-cap, which itself was placed
into a larger vial that was sealed with a crimped septum.
Samples stored at 2–8 C exhibited a pattern that was
statistically indistinguishable from those stored at room
temperature. It was hypothesized that upgrading the sealing
mechanism might improve the storage stability of formu-
lated DMTS. The goal of the present study was to test
whether DMTS formulations that were hermetically fire-
sealed in glass ampules would exhibit better storage sta-
bility than formulations stored using the prior snap-cap and
septum-sealing approach.
2 Materials and Methods
2.1 Materials
DMTS, and dimethyl disulfide (DMDS) were purchased
from Sigma Aldrich (St. Louis, MO, USA). Acetonitrile
(high-performance liquid chromatography [HPLC] grade),
water (HPLC), and ethanol were purchased from VWR
International (Suwanee, GA, USA). Poly80 was purchased
from Alfa Aesar (Haverhill, MA, USA).
2.2 DMTS Solution Preparation and Storage
A DMTS stock solution (50 mg/ml) was prepared by dis-
solving DMTS in 15% aqueous Poly80. To fully dissolve
the DMTS, vigorous hand vortexing was applied for 5 min,
followed by 30 min auto-vortexing at room temperature
[18].
2.2.1 Control Samples (Snap-Cap and Crimp Sealed)
A set of control samples was prepared by pipetting 1-ml
aliquots of DMTS stock solution into 15 snap-cap HPLC
vials (VWR International). After capping, each HPLC vial
was placed inside a larger 5-ml glass vial (Wheaton, Mil-
lville, NJ, USA). Each Wheaton vial was crimp sealed with
a rubber septum (Fig. 1). In this manner, 15 samples were
prepared and stored at 4 C for triplicate testing after 7, 14,
21, 60, and 100 days. On each testing day, the appropriate
double-sealed vials were opened and the DMTS concen-
tration was measured by HPLC. Each vial was opened and
measured only once. Because we were able to observe
clear replication of prior results showing a statistically
significant decrease of DMTS within 21 days, the 60- and
100-day samples were not measured.
2.2.2 Hermetically Sealed Samples
A hermetically sealed set of samples was prepared by
pipetting 1-ml aliquots of DMTS stock solution into 20
ampules (2 ml; Wheaton). The DMTS content of the
solutions was determined via HPLC. The ampules were
Flame-sealed 
glass ampule
Snap-cap and 
Septum-sealed 
double vial
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Fig. 1 Two approaches for storing formulated DMTS solution: the
snap-cap-sealed vial within a crimp-sealed vial, and the flame-sealed
glass ampule
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then manually flame sealed, and stored at 4 C for qua-
druplicate testing by HPLC after 7, 14, 21, 60, and
100 days.
2.3 HPLC Measurements
Samples were diluted before HPLC analysis: 990 ll of
ethanol with 0.1 mg/ml DMDS (internal standard) was
transferred into an HPLC vial; 10 ll of DMTS sample
solution was then added and the mixture was vortexed well.
For the HPLC measurement, the system was a Dionex
Ultimate 3000 UHPLC with ultraviolet–visible (UV–VIS)
detector (Thermo Scientific). Ten microliters of the diluted
sample was injected into a Phenomenex Luna 5 lm C8 (2)
100A, 250 9 4.6 mm column. The mobile phase consisted
of 60% acetonitrile and 40% water with a flow rate of
1 ml/min. The detector wavelength was 215 nm. Peak
integration was performed by using Chromeleon 7 soft-
ware. The calibration curve for this assay gave an equation
of y = 4.2038 9- 2.0367 with an R2 = 0.9972.
2.4 Statistical Analysis
All data presented are mean± standard deviation. Values
were compared using analysis of variance (ANOVA) fol-
lowed by Dunnett’s test (GraphPad Prism 5.0, GraphPad
Software Inc., San Diego, CA, USA). An unpaired t test
was applied to assess the ampule sealing effect (Fig. 2a).
Changes were considered statistically significant at
p\0.05.
3 Results
3.1 DMTS Stability Studies in Double-Sealed Vials
and Ampules
To allay initial concern that the flame used to hermetically
seal the glass ampule samples might itself influence con-
centrations, we measured the DMTS in six ampules
immediately before and after fire sealing the ampules. As
seen in Fig. 2a, no significant changes in DMTS concen-
tration were induced by the flame sealing of the ampules.
This gave us confidence to proceed with the storage-sta-
bility study in the hermetically sealed vials. The DMTS
concentrations measured in control samples decreased
systematically by 20% over 21 days (Fig. 2b). In sharp
contrast, no statistically significant changes in DMTS
concentration (Fig. 2c) were observed over a 100-day
period when the DMTS formulation was hermetically
stored in fire-sealed ampules.
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Fig. 2 Comparing the storage
stability of formulated DMTS
(50 mg/ml in 15% w/w aqueous
Poly80 solution): a The effect of
ampule flame sealing on DMTS
concentration. Statistical
analysis for A: unpaired t-test,
n = 6. b The DMTS
concentration when the
formulation was stored in
double-sealed vials (snap-cap-
sealed vial within a crimp-
sealed vial), n = 3. c The DMTS
concentration when the
formulation was stored in flame-
sealed glass ampules, n = 4.
Data are presented as
mean± standard deviation.
Statistical analysis for (b) and
(c): analysis of variance
(ANOVA) followed by
Dunnett’s test; ***p\0.001, all
groups were compared with
control
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4 Discussion
The Poly80 formulation provided a solvent system that
enhanced the solubility of the lipophilic DMTS. When the
Poly80 concentration exceeds the CMC (in this case by
about 600 times), Poly80 forms micelles. Kovacs and
colleagues determined the solubility of DMTS to be 0.13,
and 86 mg/ml, respectively, in water [10] and in the 15%
aqueous Poly80 formulation [11]. No changes in DMTS
concentration, formulation clarity, or phase were observed
upon storage. Based on this assessment, and the encapsu-
lation efficiency (EE%) calculation shown below, we
estimate that 0.2% of the DMTS in this formulation was
present as free DMTS in the water and 99.8% was asso-
ciated with the micelles both before and after storage.
EE% ¼ amount of encapsulated DMTS
total amount of DMTS
 100
¼ total amount of DMTS amount of DMTS in waterð Þ
total amount of DMTS
 100:
The enhanced solubility enables DMTS to be formulated
for intramuscular injections that can be rapidly
administered in a scenario of mass intoxication. In a
prior study of the storage stability of DMTS in double-
sealed containers, Bartling et al. [17] observed DMTS
concentration decreased in the range of 7–45% over
10 weeks of storage at 2–8 C. They carried out careful
experiments attempting to isolate the loss mechanisms.
Although these experiments did not lead to a conclusive
explanation, the authors suggested that two potential causes
of DMTS losses from non-hermetically sealed vials might
be reactions with airborne molecules and evaporation.
Based on these suggestions, it was hypothesized that
higher-quality seals might improve the storage stability of
DMTS formulations. The present study tested this
hypothesis by replacing snap-cap and crimped-septum
seals with hermetic glass seals prepared in a flame-sealing
process. The hermetic glass seals did not perturb DMTS
concentrations. More importantly, when formulated DMTS
was stored at 4 C in these hermetically sealed ampules,
the storage instability problem was overcome. No losses in
DMTS concentration were observed over the 100-day
period of this study. Because this hermetic sealing
approach shows great promise, studies of DMTS
formulation stability over longer storage periods and at
different temperatures are ongoing.
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